RESUMEN
The impact of rufloxacin and ciprofloxacin on faecal microflora was investigated in an experimental germ-free mice model into which human gastrointestinal flora was introduced and stabilized. Animals received oral doses of 10, 40 or 80 mg rufloxacin/kg, 30 or 60 mg ciprofloxacin/kg once daily for 10 days, or no treatment. Microflora was studied before, during and 1 week after treatment. No significant effect ( < 2 log reduction, p > 0.05) on aerobic microflora was observed after rufloxacin as compared to controls, except for a marked decrease in enterobacteria and a slight decrease in enterococci, staphylococci and anaerobes at the highest dose. Both doses of ciprofloxacin significantly reduced enterobacteria and clostridia, while the lower dose slightly reduced peptococci, bifidobacteria and eubacteria. The depression of the intestinal ecosystem was reversible, except for enterobacteria at the higher ciprofloxacin dose. No bacterial resistance was detected after either treatment.
Asunto(s)
Antiinfecciosos/farmacología , Bacterias/efectos de los fármacos , Ciprofloxacina/farmacología , Fluoroquinolonas , Intestinos/microbiología , Quinolonas/farmacología , Administración Oral , Animales , Antiinfecciosos/administración & dosificación , Bacterias/crecimiento & desarrollo , Ciprofloxacina/administración & dosificación , Recuento de Colonia Microbiana , Heces/microbiología , Femenino , Vida Libre de Gérmenes , Humanos , Masculino , Ratones , Ratones Endogámicos A , Pruebas de Sensibilidad Microbiana , Quinolonas/administración & dosificaciónRESUMEN
In our study we considered the possible interference of cefetamet-pivoxil with the intestinal microflora. We used 60 germ-free mice in which an intestinal microflora similar to the human one had been implanted. They were treated with 14.3 mg/Kg/die (standard dose) and a 28.6 mg/kg/die (daily dose) of cefetamet-pivoxil by oral route. The results obtained in vivo proved that cefetamet-pivoxil at therapeutic doses does not influence the normal intestinal microflora.
Asunto(s)
Bacterias/efectos de los fármacos , Ceftizoxima/análogos & derivados , Intestinos/microbiología , Animales , Ceftizoxima/farmacología , Femenino , Vida Libre de Gérmenes , Masculino , RatonesRESUMEN
The aim of our study was to evaluate the interference of fosfomycin trometanol (F.T.), at subinhibitory concentrations (1/4 and 1/8 MICs), on some urovirulence factors of Escherichia coli (12 strains). We tested fimbriae production, adhesion to uroepithelial cells, hydrophobicity, motility and hemolysin production of E. coli grown in the presence or absence of F.T. The strains tested, grown in the presence of F.T. (1/8 MIC), were less capable of adhering to uroepithelial cells, had less hemagglutination and reduced motility. This behavior was enhanced at 1/4 MIC of F.T. The hemolysin production and hydrophobicity properties present in some of our tested strains also were significantly decreased when the E. coli were grown in the presence of sub-MIC concentrations of F.T. These results suggest that F.T. may be of clinical use as treatment for acute urinary tract infection and in pyelonephritis prophylaxis.
Asunto(s)
Escherichia coli/efectos de los fármacos , Fosfomicina/farmacología , Adhesión Bacteriana/efectos de los fármacos , Movimiento Celular/efectos de los fármacos , Células Epiteliales , Epitelio/microbiología , Escherichia coli/patogenicidad , Escherichia coli/fisiología , Femenino , Hemaglutinación/efectos de los fármacos , Humanos , Pruebas de Sensibilidad Microbiana , Saccharomyces cerevisiae , Sistema Urinario/citología , Sistema Urinario/microbiología , Infecciones Urinarias/microbiología , Virulencia/efectos de los fármacosRESUMEN
The present study examines the possible interference of ceftibuten on intestinal microflora. In 60 germ-free mice, an intestinal microflora similar to the human one was implanted. The mice were then treated with a single dose and twice the therapeutic dose of ceftibuten. In another experiment, ten human volunteers were given ceftibuten in doses equivalent to 400 mg/day for 7 days in order to evaluate the ceftibuten faecal concentration, the possible interference on microflora and the quantity of indacan (as a measure of the bacterial metabolism in the gut) excreted in one day. The results obtained in vivo and in vitro have shown that ceftibuten in therapeutic doses does not alter the equilibrium of normal intestinal microflora.
Asunto(s)
Cefalosporinas/farmacología , Intestinos/microbiología , Adulto , Animales , Bacterias/efectos de los fármacos , Ceftibuteno , Heces/microbiología , Vida Libre de Gérmenes , Humanos , Intestinos/efectos de los fármacos , RatonesRESUMEN
The objective of this study was to create a stable experimental model to act as a living incubator for the main important intestinal bacteria. We have therefore inoculated germ-free mice with the most important bacteria of the human intestinal microflora, in order to study the effect of some oral antibiotics on the intestinal microflora. Sixty germ-free mice, 7 weeks old and of either sex, were inoculated orally with human faecal bacteria by means of their drinking water. Administrations were made at regular intervals following a scheme that respected some of the metabolic inter-relationships of the microorganisms used. The results showed that colonization of the germ-free mouse intestines had been achieved by most of the bacteria that had been inoculated. This "coculture" was stable in time, contrary to what happens when in-toto lyophilized faeces are administered, and the bacterial concentrations for each strains were similar to those found in human faeces.